• Views: in the last
  • 22Week
  • 17Month
  • 147Total


  • NJ A1007
  • Requires insurers to provide coverage for medications and dose-intensive chemotherapy/bone marrow transplants and umbilical cord blood transplants for treatment of sickle cell anemia.
Introduced
(1/27/2016)
In Committee
(6/1/2017)
Crossed OverPassedSignedDead/Failed/Vetoed
2016-2017 Regular Session
This bill requires hospital, medical and health service corporations, individual, small employer and large group insurers, health maintenance organizations and prepaid prescription service organizations to cover certain medically necessary treatments for sickle cell anemia. Under the bill, insurers that provide prescription drug benefits must cover any prescription drug expenses incurred in the treatment of sickle cell anemia. In addition, insurers, other than prepaid prescription organizations, must cover any expenses for treatments using dose-intensive chemotherapy/bone marrow transplantation and umbilical cord blood transplantation when those treatments are performed by certain health care facilities or performed pursuant to guidelines approved by certain medical organizations.
Financial Institutions and Insurance
Reported and Referred to Assembly Appropriations Committee  (on 6/1/2017)
 
 

Date Chamber Action Description
6/1/2017 A Reported and Referred to Assembly Appropriations Committee
6/1/2017 Assembly Financial Institutions and Insurance Hearing (19:00 6/1/2017 )
1/27/2016 A Introduced, Referred to Assembly Financial Institutions and Insurance Committee
Date Motion Yea Nay Other
Detail 6/1/2017 Assembly Financial Institutions and Insurance Committee: Reported Favorably 13 0 0